BEAM THERAPEUTICS INC

NASDAQ: BEAM (Beam Therapeutics Inc.)

Kemas kini terakhir: semalam, 11:38AM

23.44

0.04 (0.17%)

Penutupan Terdahulu 23.40
Buka 23.86
Jumlah Dagangan 950,823
Purata Dagangan (3B) 1,209,129
Modal Pasaran 1,940,963,328
Harga / Jualan (P/S) 5.49
Harga / Buku (P/B) 2.45
Julat 52 Minggu
20.84 (-11%) — 49.50 (111%)
Tarikh Pendapatan 25 Feb 2025 - 3 Mar 2025
Margin Keuntungan -41.07%
Margin Operasi (TTM) -746.40%
EPS Cair (TTM) -1.58
Pertumbuhan Hasil Suku Tahunan (YOY) -17.00%
Jumlah Hutang/Ekuiti (D/E MRQ) 20.48%
Nisbah Semasa (MRQ) 5.69
Aliran Tunai Operasi (OCF TTM) -135.81 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -38.55 M
Pulangan Atas Aset (ROA TTM) -9.27%
Pulangan Atas Ekuiti (ROE TTM) -18.29%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Bercampur
Biotechnology (Global) Bercampur Bercampur
Stok Beam Therapeutics Inc. Menurun Menurun

AISkor Stockmoo

0.3
Konsensus Penganalisis 1.0
Aktiviti Orang Dalam NA
Volatiliti Harga 2.0
Purata Bergerak Teknikal -1.5
Osilator Teknikal -0.5
Purata 0.25

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
BEAM 2 B - - 2.45
JAZZ 7 B - 17.16 1.76
CYTK 5 B - - 60.31
SPRY 1 B - - 5.10
NTLA 968 M - - 1.01
QURE 751 M - - 13.45

Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.

Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Value
% Dimiliki oleh Orang Dalam 1.48%
% Dimiliki oleh Institusi 93.14%

Pemilikan

Nama Tarikh Syer Dipegang
Mwg Management Ltd. 30 Sep 2024 2,266,934
Temasek Holdings (Private) Ltd 30 Sep 2024 1,812,972
161.85161.85126.30126.3090.7590.7555.2055.2019.6519.65Harga Sasaran MedianQ1 '20Q1 '20Q2 '20Q2 '20Q3 '20Q3 '20Q4 '20Q4 '20Q1 '21Q1 '21Q2 '21Q2 '21Q3 '21Q3 '21Q4 '21Q4 '21Q1 '22Q1 '22Q2 '22Q2 '22Q3 '22Q3 '22Q4 '22Q4 '22Q1 '23Q1 '23Q2 '23Q2 '23Q3 '23Q3 '23Q4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24
Julat 52 Minggu
20.84 (-11%) — 49.50 (111%)
Julat Harga Sasaran
24.00 (2%) — 80.00 (241%)
Tinggi 80.00 (HC Wainwright & Co., 241.30%) Beli
Median 39.00 (66.38%)
Rendah 24.00 (RBC Capital, 2.39%) Pegang
Purata 47.67 (103.37%)
Jumlah 2 Beli, 1 Pegang
Harga Purata @ Panggilan 26.92
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
HC Wainwright & Co. 09 Dec 2024 80.00 (241.30%) Beli 27.52
07 Nov 2024 80.00 (241.30%) Beli 26.10
Leerink Partners 06 Nov 2024 39.00 (66.38%) Beli 26.62
RBC Capital 06 Nov 2024 24.00 (2.39%) Pegang 26.62

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
13 Jan 2025 Pengumuman Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts
17 Dec 2024 Pengumuman Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
08 Dec 2024 Pengumuman Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting
07 Dec 2024 Pengumuman Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
06 Dec 2024 Pengumuman Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer
04 Dec 2024 Pengumuman Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader
12 Nov 2024 Pengumuman Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference
05 Nov 2024 Pengumuman Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs
05 Nov 2024 Pengumuman Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting
29 Oct 2024 Pengumuman Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting
28.9828.9826.6226.6224.2724.2721.9121.9119.5619.56Jan 7Jan 7Jan 8Jan 8Jan 10Jan 10Jan 13Jan 13Jan 14Jan 14Jan 15Jan 15Jan 16Jan 16Jan 17Jan 17

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
1.0001.0000.5000.5000.0000.000-0.500-0.500-1.000-1.000MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda